1 day Ago By Defense World Staff
Equities researchers at BTIG Research initiated coverage on shares of VYNE Therapeutics ( NASDAQ:VYNE – Get Free Report ) in a note issued to investors on Monday, Marketbeat reports. The firm set a “buy” rating and a $8.00 price target on the stock.
BTIG Research’s price target would indicate a potential upside of 193.04% from the stock’s current price. Separately, HC Wainwright restated a “buy” rating and set a $5.
75 price objective on shares of VYNE Therapeutics in a research note on Friday, November 8th. Read Our Latest Stock Report on VYNE VYNE Therapeutics Stock Up 0.4 % Institutional Inflows and Outflows A hedge fund recently bought a new stake in VYNE Therapeutics stock.
Virtu Financial LLC purchased a new position in VYNE Therapeutics Inc. ( NASDAQ:VYNE – Free Report ) during the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund purchased 16,199 shares of the company’s stock, valued at approximately $50,000.
Virtu Financial LLC owned about 0.11% of VYNE Therapeutics at the end of the most recent quarter. Institutional investors own 83.
78% of the company’s stock. About VYNE Therapeutics ( Get Free Report ) VYNE Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on developing proprietary and therapeutics for the treatment of immuno-inflammatory conditions. The company's lead product is VYN201, a locally administered pan- bromodomain and extra-terminal (BET) inhibitor soft drug to address diseases involving multiple, diverse inflammatory cell signaling pathways with low systemic exposure.
Further Reading Five stocks we like better than VYNE Therapeutics The Significance of Brokerage Rankings in Stock Selection Super Micro Computer Soars 28%: Is It Really Out of the Woods? How to Calculate Stock Profit Traders Are Flocking Back to Oil: What’s Fueling the Optimism Retail Stocks Investing, Explained 3 Hot Stock Trends to Ride Into 2025 Receive News & Ratings for VYNE Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for VYNE Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter ..
